These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 20491003)

  • 21. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.
    Kilian R; Matschinger H; Löeffler W; Roick C; Angermeyer MC
    J Ment Health Policy Econ; 2002 Mar; 5(1):21-31. PubMed ID: 12529567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
    Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
    Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of schizophrenia: let's talk dollars and sense.
    Buckley PF
    Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine for refractory schizophrenia: the Illinois experience.
    Buckman RW; Malan RD
    J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling of annual treatment costs and health outcomes of antipsychotic agents for schizophrenic populations. Based on a presentation by Josephine Mauskopf, PhD.
    Am J Manag Care; 1999 Jul; 5(10 Suppl):S601-11. PubMed ID: 10539495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of treatment of schizophrenia in six European countries.
    Salize HJ; McCabe R; Bullenkamp J; Hansson L; Lauber C; Martinez-Leal R; Reinhard I; Rössler W; Svensson B; Torres-Gonzalez F; van den Brink R; Wiersma D; Priebe S
    Schizophr Res; 2009 Jun; 111(1-3):70-7. PubMed ID: 19401265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Guidelines for budget impact analysis of health technologies in Brazil].
    Ferreira-Da-Silva AL; Ribeiro RA; Santos VC; Elias FT; d'Oliveira AL; Polanczyk CA
    Cad Saude Publica; 2012 Jul; 28(7):1223-38. PubMed ID: 22729254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [From Model to Regional Regular Care - Long-Term Effects of a Regional Budget].
    Deister A; Michels R
    Psychiatr Prax; 2022 Jul; 49(5):237-247. PubMed ID: 34102696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of drug budgets. Neurologists do not have confidence in Glasgow's method of managing drugs budget.
    Ballantyne JP; Behan PO; Bone I; Durward WF; Grosset D; Kennedy PG; Metcalfe RA; O'Leary CP; Petty RH; Thomas M; Willison HJ; Duncan R
    BMJ; 1999 Mar; 318(7187):874. PubMed ID: 10092279
    [No Abstract]   [Full Text] [Related]  

  • 31. German doctors are unhappy about drugs budget.
    Tuffs A
    BMJ; 1999 Aug; 319(7209):536A. PubMed ID: 10463889
    [No Abstract]   [Full Text] [Related]  

  • 32. Proposal for a Comprehensive Definition of Budget Impact Analysis.
    Bierbaum M
    Value Health; 2014 Nov; 17(7):A548-9. PubMed ID: 27201781
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Secondary data for budget impact analyses].
    Sindern J; Schröder-Bernhardi D; Slawik L
    Gesundheitswesen; 2010 Jun; 72(6):356-62. PubMed ID: 20491003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.